Short-term effects of an anti- inflammatory treatment on clinical parameters and serum levels of c-reactive protein and proinflammatory cytokines in subjects with periodontitis

Journal of Periodontology

Volumn 80, Issue 6, 2009, Pages 892-900

  Renvert, Stefan ^a,b,c   Lindahl, Christel ^a,d   Roos Jansåker, Ann Marie ^d   Lessemi, Jan ^e  

^a KRISTIANSTAD UNIVERSITY   (Sweden)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c BLEKINGE INSTITUTE OF TECHNOLOGY   (Sweden)

^d Public Dental Health Service   (Sweden)

^e Horizon CombinatoRx   (United States)

Author keywords

Anti inflammatory agents; C reactive protein; Cytokines; Periodontal disease

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTACOID; C REACTIVE PROTEIN; CRX 102; DIPYRIDAMOLE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HUMAN; MALE; MIDDLE AGED; PERIODONTITIS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; DENTAL SCALING; DIPYRIDAMOLE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GINGIVAL HEMORRHAGE; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PERIODONTAL POCKET; PERIODONTITIS; PLACEBOS; PREDNISOLONE; ROOT PLANING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649908743     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2009.080552     Document Type: Article

References (48)

1. Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999;70:13-29.
2. Satcher D. Oral Health in America: A Report by the Surgeon General. Rockville, MD: U.S Department of Health and Human Services; 2000. NIH publication no 00-4713.
3. Slots J, Ting M. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: Occurrence and treatment. Periodontol 2000 1999;20:82-121.
4. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000 2005;38:135-187.
5. Holt SC, Ebersole JL. Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia: The ''red complex'', a prototype polybacterial pathogenic consortium in periodontitis. Periodontol 2000 2005;38:72-122.
6. Ebersole JL, Machen RL, Steffen MJ, Willmann DE. Systemic acute-phase reactants, C-reactive protein and haptoglobin, in adult periodontitis. Clin Exp Immunol 1997;107:347-352.
7. Loos BG, Craandijk J, Hoek F, Wertheim-van Dillen PM, Van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 2000; 71:1528-1534.
8. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001;72:1221-1227.
9. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol 2003;23:1245-1249.
10. Buhlin K, GustafssonA, Pockley AG,Frostega°rd J, Klinge B. Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J 2003;24:2099-2107.
11. Craig RG, Yip JK, So MK, Boylan RJ, Socranksy SS, Haffajee AD. Relationship of destructive periodontal disease to the acute-phase response. J Periodontol 2003;74:1007-1016.
12. D'Aiuto F, Parkar M, Andreou G, et al. Periodontitis and systemic inflammation: Control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res 2004;83:156-160.
13. Pietila K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J 1993;14:915-919.
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CVH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
15. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 2002;105:2-4.
16. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
17. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003;21:315- 325.
18. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol 2005;96:1374-1378.
19. Ray KK, Cannon CP, Cairns R, et. al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46: 1417-1424.
20. DeStefano F, Anda RF, Kahn HS, et al. Dental disease and risk of coronary heart disease and mortality. BMJ 1993;306:688-691.
21. Mattila KJ. Dental infections as a risk factor for acute myocardial infarction. Eur Heart J 1993;14(Suppl. K): 51-53.
22. Mattila K. Does periodontitis cause heart disease? Eur Heart J 2003;24:2079-2080.
23. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol 1996;67:1123-1137.
24. Morrison HI, Ellison LF, Taylor GW. Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J Cardiovasc Risk 1999;6:7-11.
25. Joshipura KJ, Rimm EB, Douglass CW, et al. Poor oral health and coronary heart disease. J Dent Res 1996; 75:1631-1636.
26. Lessem J, Drisko C, Greenwell H, et al. Are cardiac transplant patients more likely to have periodontitis? A case record study. J Int Acad Periodontol 2002;4:95- 100.
27. Rutger Persson G, Ohlsson O, Pettersson T, Renvert S. Chronic periodontitis, a significant relationship with acute myocardial infarction. Eur Heart J 2003;24: 2108-2115.
28. Persson GR, Pettersson T, Ohlsson O, Renvert S. Highsensitivity serum C-reactive protein levels in subjects with or without myocardial infarction or periodontitis. J Clin Periodontol 2005;32:219-224.
29. Ide M, McPartlin D, Coward PY, Crook M, Lumb P, Wilson RF. Effect of treatment of chronic periodontitis on levels of serum markers of acute-phase inflammatory and vascular responses. J Clin Periodontol 2003; 30:334-340.
30. Mattila K, Vesanen M, Valtonen V, et al. Effects of treating periodontitis on C-reactive protein levels: A pilot study. BMC Infect Dis 2002;2:30-33.
31. Iwamoto Y, Nishimura F, Soga Y, et al. Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin levels in patients with chronic periodontitis. J Periodontol 2003;74:1231-1236.
32. Price ER, Manivasakam P, Robinson E, et al. Molecular insight into steroid dissociation of CRx-102, a clinically active immuno modulatory agent. Arthritis Rheum 2006;54(Suppl.):529.
33. Kvien TK, Fjeld E, Slatkowsky-Christensen B, et al. Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis 2008;67:942-948.
34. Kvien T, Slatkowsky-Christensen B, Fjeld E, et al. The responsiveness of joint count and patient reported measures in Hand Osteoarthritis (HOA): Analyses from a placebo-Controlled Randomized Trial (RCT). Osteoarthritis Cartilage 2006;14(Suppl. B):121.
35. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1b, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000;71:1535-1545.
36. Goutoudi P, Diza E, Arvanitidou M. Effect of periodontal therapy on crevicular fluid interleukin-1b and interleukin- 10 levels in chronic periodontitis. J Dent 2004;32:511-520.
37. Offenbacher S, Elter JR, Lin D, Beck JD. Evidence for periodontitis as a tertiary vascular infection. J Int Acad Periodontol 2005;7:39-48.
38. Mercado FB, Marshall R, Klestov A, Bartold P. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779-787.
39. Renvert S, Pettersson T, Ohlsson O, Persson GR. Bacterial profile and burden of periodontal infection in subjects with a diagnosis of acute coronary syndrome. J Periodontol 2006;77:1110-1119.
40. Wu T, Trevisan M, Genco RJ, Falkner KL, Dorn JP, Sempos CT. Examination of the relation between periodontal health status and cardiovascular risk factors: Serum total and high-density lipoprotein cholesterol, C-reactive protein, and plasma fibrinogen. Am J Epidemiol 2000;151:273-282.
41. Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 1996;67:1103-1113.
42. Williams RC, Paquette D, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: A controlled trial. J Periodontol 2001;72:1535-1544.
43. Garrett S, Johnson L, Drisko C, et al. Two multi-center studies evaluating locally delivered doxycycline hyclate, placebo control, oral hygiene, and scaling and root planing in the treatment of periodontitis. J Periodontol 1999;70:490-503.
44. Caton JG, Ciancio SG, Blieden TM, et al. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: Post-treatment effects. J Clin Periodontol 2001;28:782-789.
45. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003;8:12-37.
46. Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med 2007;356:911-920.
47. D'Aiuto F, Parkar M, Tonetti MS. Periodontal therapy: A novel acute inflammatory model. Inflamm Res 2005;54:412-414.
48. Elliot PJ, Keegan M, Avery W, Borisy AA. CRx-102: A novel, orally available, syncretic agent with significant in-vitro and in-vivo immuno-modulatory activity and a dissociated steroid profile. Arthritis Rheum 2004;50(Suppl.):S370-S371.